Virax Holdings Appendix 4E and 2014 Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- US FDA Reactivates PTXs IND for PTX-100 Breast Cancer Trial
- Two new Patents granted to Protect Lead Asset PTX-200
- PTX Acquires Worldwide License for Cancer Biomarker p27
- PTX-200 Phase 1B/2 Clinical Trial Update
- Proposed Grant of Options to Non-Executive Directors
Later from Prescient Therapeutics
- Intellectual Property Report Update
- Reinstatement to Official Quotation - 19 November 2013
- Response to ASX Aware Letter
- Virax to acquire advanced cancer platform from Yale Uni
- Dutchess Continuous Investment Agreement - 10 January 2012
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics